default author photo

Qinqin Xu

Qinghai Provincial People's Hospital - Department of Medical Oncology

China

SCHOLARLY PAPERS

5

DOWNLOADS

318

TOTAL CITATIONS

0

Scholarly Papers (5)

1.

Overall Survival According to Time-of-Day of Treatment Administration in 713 Patients Receiving Immunochemotherapy as First Line Treatment Protocol for Advanced Non-Small Cell Lung Cancer: A Bicentric Bicontinental Study

Number of pages: 25 Posted: 18 Oct 2024
Central South University - Hunan Cancer Hospital, University of Paris-Saclay, Central South University - Department of Medical Oncology, University of Paris-Saclay, Central South University - Hunan Cancer Hospital, University of Paris-Saclay, Central South University - Hunan Cancer Hospital, Université Paris XIII Nord - Avicenne Hospital, Central South University - Hunan Cancer Hospital, Université Paris XIII Nord - Avicenne Hospital, Central South University - Hunan Cancer Hospital, Université Paris XIII Nord - Avicenne Hospital, Central South University - Department of Dermatology, Central South University - Department of Dermatology, Qinghai Provincial People's Hospital - Department of Medical Oncology, University of Versailles - Clinical Research Unit, Northeastern Great Paris Hospital Group, Central South University - Hunan Cancer Hospital, University of Paris-Saclay, Central South University - Department of Medical Oncology, Hôpital Avicenne (APHP), Central South University - Department of Medical Oncology and University of Paris-Saclay - UPR “Chronothérapie, Cancers, et Transplantation”
Downloads 117 (608,822)

Abstract:

Loading...

Circadian rhythms, Chronotherapy, Immune checkpoint inhibitors, Time of day of administration, Lung cancer, Immuno-chemotherapy, Chronopharmacology, Circadian medicine

2.

Antitumor Activity of First-Line Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancers: A Large Cohort, Multi-Center, Retrospective Study

Number of pages: 27 Posted: 28 Oct 2020
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Central South University - Department of Medical Oncology, Qinghai Provincial People's Hospital - Department of Medical Oncology, Central South University - Department of Medical Oncology, Burning Rock Biotech, Burning Rock Biotech, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Huazhong University of Science and Technology (Formerly Tongi Medical University) - Department of Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Tongji University School of Medicine - Department of Pathology, Department of Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Department of Genetics, School of Life Science, Anhui Medical University, Chinese Academy of Sciences (CAS) - Institute of Basic Medicine and Cancer (IBMC), Department of Radiotherapy; Qilu Hospital of Shandong University, Huazhong University of Science and Technology - Cancer Center, Chinese Academy of Sciences (CAS) - Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Department of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, First Affiliated Hospital, China Medical University, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Chinese Academy of Sciences (CAS) - Department of Medical Oncology, University of California, Irvine - Chao Family Comprehensive Cancer Center and Central South University - Department of Medical Oncology
Downloads 72 (860,052)

Abstract:

Loading...

ROS1 fusion, ROS1 gene rearrangements, crizotinib, non-CD74 ROS1 fusions, crizotinib resistance mechanism

3.

Potential Utility of Albumin-Bilirubin (ALBI) and Body Mass Index (BMI)-Based Logistic Model to Predict Survival Outcome in Non-Small Cell Lung Cancer with Liver Metastasis Treated with PD-1 Inhibitor

Number of pages: 52 Posted: 21 Aug 2023
Central South University - Department of Medical Oncology, Qinghai Provincial People's Hospital - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Shanghai Jiao Tong University (SJTU), Hunan University of Medicine - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Huazhong University of Science and Technology - Cancer Center, Huazhong University of Science and Technology - Cancer Centre, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Huazhong University of Science and Technology - Cancer Centre, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 57 (989,921)

Abstract:

Loading...

albumin-bilirubin grading system, immune checkpoint inhibitor, liver metastasis non-small cell lung cancer, prognostic markers

4.

PD-1 Blockade Plus Chemotherapy for EGFR-Mutant, EGFR Tyrosine Kinase Inhibitor-Pretreated Non-Small Cell Lung Cancer: A Multicenter Retrospective Study on Efficacy and Biomarker Exploration

Number of pages: 66 Posted: 31 May 2022
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Qinghai Provincial People's Hospital - Department of Medical Oncology, Shanghai Jiao Tong University (SJTU) - Department of Pathology, Hunan University of Medicine - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Huazhong University of Science and Technology - Cancer Center, Huazhong University of Science and Technology - Cancer Centre, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Huazhong University of Science and Technology - Cancer Centre, Central South University - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 52 (1,041,696)

Abstract:

Loading...

Non-small cell lung cancer, immune checkpoint inhibitor, EGFR, tyrosine kinase inhibitors, lymphocyte subsets model

5.

Sintilimab Plus Docetaxel as Second-Line Therapy of Advanced Non-Small Cell Lung Cancer Without Targetable Mutations: A Phase II Efficacy and Biomarker Study

Number of pages: 28 Posted: 25 Apr 2022
Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Central South University - Hunan Cancer Hospital, Shanghai Jiao Tong University (SJTU) - State Key Laboratory of Oncogenes and Related Genes, Central South University - Hunan Cancer Hospital, Qinghai Provincial People's Hospital - Department of Medical Oncology and Central South University - Department of Medical Oncology
Downloads 20 (1,459,862)

Abstract:

Loading...

Sintilimab plus docetaxel, NSCLC, CTC-PD-L1, multiplex immunofluorescence